<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941379</url>
  </required_header>
  <id_info>
    <org_study_id>Registry AU-011-401</org_study_id>
    <nct_id>NCT03941379</nct_id>
  </id_info>
  <brief_title>A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)</brief_title>
  <official_title>A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aura Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aura Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational research study is to follow participants who have been
      treated with either AU-011 or observation and/or received standard of care therapy while
      participating in a previous Aura Biosciences clinical research study to assess the long-term
      safety and effectiveness of AU-011 and standard of care therapy. This study will collect
      information from procedures conducted as part of routine follow-up eye care and cancer care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center long-term observational Registry of patients with Primary Choroidal
      Melanoma (CM) or Indeterminate Lesions (ILs) The Registry will initially be open to patients
      who have previously participated in an Aura Biosciences sponsored clinical trial for their
      primary Choroidal Melanoma or Indeterminate Lesions.

      All patients will be followed for a minimum of 5 years (including time enrolled in an Aura
      sponsored clinical trial), until withdrawal of consent, or until death whichever comes first.

      No interventions will be required as part of the Registry. Data collection will be based on
      information anticipated to be available based on the standard of care for patients with CM or
      IL; these patients are routinely followed at 6-month intervals by their treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Related Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Treatment related adverse events will be assessed and graded using CTCAE v5.0. The number and percentage of patients with treatment related adverse events will be summarized.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Choroidal Melanoma</condition>
  <condition>Indeterminate Lesions of Eye</condition>
  <arm_group>
    <arm_group_label>Patients previously participated in an Aura Biosciences study</arm_group_label>
    <description>Patients with Choroidal Melanoma or Indeterminate Lesions.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary Choroidal Melanoma and Indeterminate Lesions who participated in
        previous Aura Biosciences sponsored clinical trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been clinically diagnosed with primary CM or IL at the time of entry to a
             previous Aura Biosciences sponsored clinical trial.

          -  Have received AU-011 or assigned to an observation cohort in a previous Aura sponsored
             clinical trial.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijit Narvekar, MBBS MS DPM</last_name>
    <role>Study Director</role>
    <affiliation>Aura Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rochelle Summerfelt, MS</last_name>
    <phone>(773) 855-8157</phone>
    <email>rsummerfelt@aurabiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abhijit Narvekar, MBBS MS DPM</last_name>
    <phone>617-250-7255</phone>
    <email>anarvekar@aurabiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gutierrez</last_name>
      <phone>617-391-5959</phone>
      <email>MariaElena_Gutierrez@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grayson Hanlon</last_name>
      <phone>617-573-5627</phone>
      <email>Grayson_Hanlon@meei.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ivana Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Mellert</last_name>
      <phone>248-288-9132</phone>
      <phone_ext>1315</phone_ext>
      <email>kmellert@arcpc.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Capone Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andi Gilchrist, BS CMSS</last_name>
      <phone>612-746-3880</phone>
      <email>agilchrist@retinadocs.com</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Moreno</last_name>
      <phone>612-746-3880</phone>
      <email>cmoreno@retinadocs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abdhish R Bhavsar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Schwendeman</last_name>
      <phone>215-928-3105</phone>
      <email>rachel@shields.md</email>
    </contact>
    <contact_backup>
      <last_name>BaoNgoc Nguyen</last_name>
      <phone>(215) 928-7161</phone>
      <email>bnguyen@shields.md</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Shields, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsey L Moore, CMSS</last_name>
      <phone>713-394-7575</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy C Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ocularmelanoma.org/</url>
    <description>Ocular Melanoma</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>Indeterminate Lesions of Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

